Biliary tract carcinomas: from chemotherapy to targeted therapy.
Biliary tract carcinomas (BTC) are a group of tumours arising from the epithelial cells of intra- and extra-hepatic biliaryducts and the gallbladder, characterised by a poor prognosis. Surgery is the only curative procedure, but the risk of recurrence is high and furthermore, the majority of patients present with unresectable disease at the time of diagnosis. Systemic therapy is the mainstay of treatment for patients who present recurrent or metastatic disease. Progress has been made in the last decade to identify the most effective chemotherapy regimens, with the recent recommendation of the combination of gemcitabine-cisplatin as the standard schedule. Comprehension of the molecular basis of cholangiocarcinogenesis and tumour progression has recently led to the experimentation of targeted therapies in patients with BTC, demonstrating promising results. In this review we will discuss the clinical experience with systemic treatment for BTC, focusing on future directions with targeted therapies.
Department of Medical Oncology, University of Turin Medical School, Institute for Cancer Research and Treatment (IRCC), Candiolo, Italy. donatella.marino@ircc.it
Donatella
D
Marino
Francesco
F
Leone
Giuliana
G
Cavalloni
Celeste
C
Cagnazzo
Massimo
M
Aglietta
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D057890:Epigenomics; D023281:Genomics; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging